DARS-AS1:一个重要的瘤性LncRNA调节器,具有癌症预后和治疗潜力
Jian Shu1,2, Kejiang Xia3, Hongliang Luo1
1Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330008, Jiangxi, China.
International journal of medical sciences
|February 7, 2024
概括
阿斯巴提尔-tRNA合成酶抗理性RNA 1 (DARS-AS1) 在许多癌症中被上调,作为一种瘤基因. 这篇评论详细介绍了DARS-AS1的细节.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 阿斯巴提尔-tRNA合成酶抗理性RNA 1 (DARS-AS1) 在各种癌症类型中经常被上调.
- 它的异常表达与致癌作用有关,并影响瘤细胞生物学.
- 了解DARS-AS1的功能对于癌症研究至关重要.
研究的目的:
- 审查DARS-AS1失调与癌症患者生存率低下之间的相关性.
- 综合分析DARS-AS1在各种癌症中的多方面的作用和分子机制.
- 为了突出DARS-AS1治疗应用研究的最新进展.
主要方法:
- 关于DARS-AS1在癌症中的现有研究的文献综述.
- 使用癌症基因组图谱 (TCGA) 数据进行全癌症分析.
- 合成关于分子机制,ceRNA网络和信号通路的信息.
主要成果:
- 在DARS-AS1失调和不良的生存预测之间存在显著的相关性.
- DARS-AS1扮演着各种各样的致癌作用,影响瘤进展和治疗耐药性.
- 分子机制涉及ceRNA网络和特定的信号通路.
结论:
- DARS-AS1是一种关键瘤基因,在癌症中具有显著的临床价值.
- 对DARS-AS1机制的进一步研究可以为预后评估和治疗策略提供信息.
- 准DARS-AS1有望为有效的癌症治疗和管理提供希望.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
Cancer Survival Analysis
348
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
348


